Abstract

BackgroundFluid removal during dialysis, also known as ultrafiltration (UF), leads to intradialytic hypotension (IDH) in a significant number of patients treated with hemodialysis (HD) and is associated with an increase in morbidity and mortality. At present, there are no accepted standards of practice for the prevention or treatment of IDH. Relative blood volume monitoring (BVM) is based on the concept that the hematocrit increases with UF, relative to the patient’s baseline hematocrit. The use of BVM biofeedback, whereby the HD machine automatically adjusts the rate of UF based on the relative blood volume, has been proposed for the prevention of IDH.Methods/DesignThis is a 22-week randomized crossover trial. Participants undergo a 4-week run-in phase to standardize medications and dialysis prescriptions. Subsequently, participants are randomized to standard HD or to BVM biofeedback for a period of 8 weeks followed by a 2-week washout phase before crossing over. The dialysis prescription remains identical for both arms. The primary outcome is the frequency of symptomatic IDH as defined by an abrupt drop in the systolic blood pressure of ≥20 mm Hg accompanied by headache, dizziness, loss of consciousness, thirst, dyspnea, angina, muscle cramps or vomiting. Secondary outcomes include the number of symptomatic IDH episodes and any reduction in IDH episodes, nursing interventions, dialysis adequacy, total body water, extra- and intracellular fluid volumes, brain natriuretic peptide and cardiac troponin levels, blood pressure, antihypertensive medication use, patient symptoms and quality of life.DiscussionOur study will determine the impact of using BVM biofeedback to prevent IDH and other serious adverse events in susceptible patients.Trial registrationClinicaltrials.gov NCT01988181 (6 November 2013).Electronic supplementary materialThe online version of this article (doi:10.1186/1745-6215-15-483) contains supplementary material, which is available to authorized users.

Highlights

  • Fluid removal during dialysis, known as ultrafiltration (UF), leads to intradialytic hypotension (IDH) in a significant number of patients treated with hemodialysis (HD) and is associated with an increase in morbidity and mortality

  • Our study will determine the impact of using blood volume monitoring (BVM) biofeedback to prevent IDH and other serious adverse events in susceptible patients

  • Randomized studies assessing the role of BVM and BVM-guided UF biofeedback in the prevention of IDH are limited and of low quality

Read more

Summary

Discussion

Randomized studies assessing the role of BVM and BVM-guided UF biofeedback in the prevention of IDH are limited and of low quality. In a 16-week randomized crossover study by Dasselaar et al, 28 hypertensive patients were randomized to either BVM-guided UF and sodium biofeedback or standard HD for blood pressure and volume control. A recent meta-analysis of six studies using BVM-guided biofeedback reported a 39% overall reduction in the number of dialysis sessions complicated by IDH [55]. One randomized crossover study (26 HD participants) examined the impact of BVM-guided UF biofeedback on patient symptoms during dialysis. A prospective multi-center triple-arm parallelgroup crossover randomized controlled trial is in progress It is comparing BVM-guided UF biofeedback and blood thermal monitoring temperature biofeedback, to BVMguided UF and sodium biofeedback, and to standard HD in fluid overloaded HD patients. All authors read this manuscript; they approve of its publication and agree to be accountable for the accuracy and integrity of the work

Background
Methods/Design
Part 1
Renal Data System US: USRDS 2012 Annual Data Report
Findings
11. Schreiber MJ
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call